Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
23.29 USD | -2.06% | +3.37% | -23.89% |
Financials (USD)
Sales 2024 * | 126M | Sales 2025 * | 179M | Capitalization | 2.89B |
---|---|---|---|---|---|
Net income 2024 * | -313M | Net income 2025 * | -304M | EV / Sales 2024 * | 19.6 x |
Net cash position 2024 * | 426M | Net cash position 2025 * | 313M | EV / Sales 2025 * | 14.3 x |
P/E ratio 2024 * |
-8.53
x | P/E ratio 2025 * |
-9.1
x | Employees | 525 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 95.51% |
Latest transcript on Arrowhead Pharmaceuticals, Inc.
1 day | -2.06% | ||
1 week | +3.37% | ||
Current month | -18.57% | ||
1 month | -14.41% | ||
3 months | -29.02% | ||
6 months | -6.95% | ||
Current year | -23.89% |
Managers | Title | Age | Since |
---|---|---|---|
Chief Executive Officer | 54 | 07-11-30 | |
Director of Finance/CFO | 57 | 08-12-31 | |
Peter Carignan
CTO | Chief Tech/Sci/R&D Officer | - | 22-07-31 |
Members of the board | Title | Age | Since |
---|---|---|---|
Douglass Given
CHM | Chairman | 71 | 10-11-22 |
Michael Perry
BRD | Director/Board Member | 64 | 11-12-18 |
Adeoye Olukotun
BRD | Director/Board Member | 79 | 20-08-31 |
Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
0.40% | 0 M€ | 0.00% | - | |
0.35% | 0 M€ | 0.00% | - |
Date | Price | Change | Volume |
---|---|---|---|
24-04-24 | 23.29 | -2.06% | 813,628 |
24-04-23 | 23.78 | -0.59% | 828,397 |
24-04-22 | 23.92 | +7.12% | 1,080,438 |
24-04-19 | 22.33 | -1.24% | 965,833 |
24-04-18 | 22.61 | +0.36% | 1,300,210 |
Delayed Quote Nasdaq, April 24, 2024 at 04:00 pm EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-23.89% | 2.95B | |
-1.51% | 105B | |
+3.22% | 97.5B | |
+1.86% | 22.19B | |
-16.53% | 21.33B | |
-8.49% | 18.68B | |
-42.33% | 16.6B | |
-20.09% | 14.52B | |
+5.47% | 14.09B | |
+28.85% | 10.99B |
- Stock Market
- Equities
- ARWR Stock